MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer
Stephen Sener(University of Southern California), Julie E. Lang(University of Southern California), Yuliya Olimpiadi(University of Southern California), Rachel E. Sargent(University of Southern California), Andrew Alabd(University of Southern California), Nicole M. Zaremba(University of Southern California), Connie Lee(University of Michigan), Vivian LeTran(University of Southern California), Maria Nelson(University of Southern California), Tejas Manchandia(University of Southern California)
Cited by 32
Related Papers
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
|Blood|2018|250
Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer
|JAMA Oncology|2020|225
Animal movements in fire‐prone landscapes
|Biological reviews/Biological reviews of the Cambridge Philosophical Society|2018|184